Mallax is a new pharma company with Swedish origins.
With a combination of acquisitions and collaborations we aim to build a portfolio of established pharmaceuticals and OTC products for customers and patients across Europe.
About Mallax Pharma
Sustainability, medical need, and profitable growth are cornerstones of Mallax’s strategy, and they will define how we operate and build our company. Our aim is to build a new leading pharma and healthcare company in Europe.
In 2021, Mallax acquired Sana Pharma Medical AS, a Nordic pharma company headquartered in Oslo. Mallax is the holding company, and all operational activities are carried out through Sana Pharma Medical.
News
1 July 2021 Mallax acquires Sana Pharma Medical and creates a new Nordic pharmaceutical platform. Download full press release.
20 December 2020 Impilo and Anders Larnholt form a partnership to create a new pan- European pharmaceutical platform. Download full press release.
